Remaining Candidates For the NME Class of 2007
This article was originally published in Pharmaceutical Approvals Monthly
Remaining Candidates For The NME Class Of 2007
You may also be interested in...
Only three NDAs for new molecular entities have user fee goal dates in the remainder of 2007, which implies a marked slow-down in the pace of NME actions after FDA’s busy October.
Redeeming a priority review voucher obtained by developing a drug for a tropical disease will cost companies $6.1 million in fiscal 2011